Audit 358832

FY End
2024-12-31
Total Expended
$835,170
Findings
0
Programs
8
Year: 2024 Accepted: 2025-06-13

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
64.054 Research and Development $195,096 - 0
93.279 Drug Use and Addiction Research Programs $133,155 - 0
93.350 National Center for Advancing Translational Sciences $54,076 - 0
12.420 Military Medical Research and Development $31,479 - 0
93.855 Allergy and Infectious Diseases Research $26,760 - 0
93.866 Aging Research $22,225 - 0
93.838 Lung Diseases Research $4,163 - 0
93.837 Cardiovascular Diseases Research $1,767 - 0

Contacts

Name Title Type
JXPVN9BZLZ15 Felix Oliver Auditee
2024627701 Tina Peacher Auditor
No contacts on file

Notes to SEFA

Title: NOTE A – BASIS OF PRESENTATION Accounting Policies: NOTE A – BASIS OF PRESENTATION The accompanying Schedule of Expenditures of Federal Awards (the “Schedule”) includes the federal grant activity of Institute for Clinical Research, Inc. (“ICR”) under programs of the federal government for the year ended December 31, 2024. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of ICR, it is not intended to and does not present the financial position, changes in net assets, or cash flows of ICR. NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Expenditures reported in the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein, certain types of expenses are not allowable or are limited to reimbursement. NOTE C – INDIRECT COST RATE ICR has elected not to use the 10 percent de minimis indirect cost rate allowed under the Uniform Guidance. De Minimis Rate Used: N Rate Explanation: ICR has elected not to use the 10 percent de minimis indirect cost rate allowed under the Uniform Guidance since it was not applicable to the federal grant programs. The accompanying Schedule of Expenditures of Federal Awards (the “Schedule”) includes the federal grant activity of Institute for Clinical Research, Inc. (“ICR”) under programs of the federal government for the year ended December 31, 2024. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of ICR, it is not intended to and does not present the financial position, changes in net assets, or cash flows of ICR.
Title: NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Policies: NOTE A – BASIS OF PRESENTATION The accompanying Schedule of Expenditures of Federal Awards (the “Schedule”) includes the federal grant activity of Institute for Clinical Research, Inc. (“ICR”) under programs of the federal government for the year ended December 31, 2024. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of ICR, it is not intended to and does not present the financial position, changes in net assets, or cash flows of ICR. NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Expenditures reported in the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein, certain types of expenses are not allowable or are limited to reimbursement. NOTE C – INDIRECT COST RATE ICR has elected not to use the 10 percent de minimis indirect cost rate allowed under the Uniform Guidance. De Minimis Rate Used: N Rate Explanation: ICR has elected not to use the 10 percent de minimis indirect cost rate allowed under the Uniform Guidance since it was not applicable to the federal grant programs. Expenditures reported in the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein, certain types of expenses are not allowable or are limited to reimbursement.
Title: NOTE C – INDIRECT COST RATE Accounting Policies: NOTE A – BASIS OF PRESENTATION The accompanying Schedule of Expenditures of Federal Awards (the “Schedule”) includes the federal grant activity of Institute for Clinical Research, Inc. (“ICR”) under programs of the federal government for the year ended December 31, 2024. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of ICR, it is not intended to and does not present the financial position, changes in net assets, or cash flows of ICR. NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Expenditures reported in the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein, certain types of expenses are not allowable or are limited to reimbursement. NOTE C – INDIRECT COST RATE ICR has elected not to use the 10 percent de minimis indirect cost rate allowed under the Uniform Guidance. De Minimis Rate Used: N Rate Explanation: ICR has elected not to use the 10 percent de minimis indirect cost rate allowed under the Uniform Guidance since it was not applicable to the federal grant programs. ICR has elected not to use the 10 percent de minimis indirect cost rate allowed under the Uniform Guidance.